Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Fidia Spa ( (IT:FDA) ) just unveiled an update.
Fidia has converted two bonds from the fourth tranche of its 2026 convertible bond loan reserved for Global Growth Holding Limited, issuing 2,000,000 new shares at a conversion price of €0.01 per share. The newly issued shares are immediately admitted to trading on the regulated market under the prospectus already in force, modestly diluting existing shareholders while strengthening the company’s equity base.
Following this latest conversion, the convertible bond loan has been subscribed for a total nominal €1 million, with the related capital increase subscribed for €890,000 and 11 bonds still outstanding and unconverted. As a result, Fidia’s share capital rises by €20,000 to €10,737,761.90, and the total number of shares increases to 48,542,927, marking continued progress in the company’s structured financing plan with GGHL.
The most recent analyst rating on (IT:FDA) stock is a Sell with a EUR0.11 price target. To see the full list of analyst forecasts on Fidia Spa stock, see the IT:FDA Stock Forecast page.
More about Fidia Spa
Fidia S.p.A., based in Turin and listed on Euronext Milan, is a leading provider of high-performance integrated milling systems, numerical controls and CAM software for complex shapes. The group primarily serves the automotive mold and aerospace sectors, offering end-to-end solutions that span the entire milling process from machining program definition to the finished component.
YTD Price Performance: -82.50%
Average Trading Volume: 1,336,175
Technical Sentiment Signal: Strong Sell
Current Market Cap: €645.1K
See more insights into FDA stock on TipRanks’ Stock Analysis page.